electroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC
July 13 2023 - 8:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine and wellness company, announced today that ReletexTM by
Reliefband, the first and only FDA cleared non-invasive
neuromodulation device available by prescription for nausea and
vomiting, will be distributed and billed exclusively by
electroCore, Inc. within the Department of Veterans Affairs (VA)
and other Federal Supply Schedule (FSS) eligible entities.
“Reliefband is a leading innovator in wearable
technology for the treatment of nausea and vomiting,” commented
Rich Ransom, Chief Executive Officer of Reliefband Technologies.
“Partnering with electroCore to distribute our prescription
non-invasive, non-drug, neuromodulation device seemed like a
natural fit. We are excited about the collaboration and hopeful the
relationship will provide our veterans access to another FDA
cleared non-drug solution.”
“We are thrilled to be offering the Reletex
product within VA hospitals and other FSS eligible entities,”
commented Dan Goldberger, Chief Executive Officer of
electroCore. “We continue to build out our commercial sales
organization and look for unique and complementary therapies which
can be made available to our customer base. The drug-free,
patient-controlled Reletex product is ideal for veterans suffering
from nausea and vomiting and we believe it will be well adopted by
customers who utilize neuromodulation devices such as our existing
gammaCore™ therapy to treat medical conditions.”
About Reliefband Technologies, LLCReliefband is
a world leader in neuromodulation and wearable technology. The
company’s patented, clinically proven wearable solution quickly
prevents and effectively treats nausea and vomiting. Its unique,
FDA-cleared neuromodulation technology was originally developed for
use in hospitals and alters nerve activity through targeted
delivery of gentle pulses to the underside of the wrist to “turn
off” feelings of nausea and vomiting. Reliefband is a drug-free
alternative that eliminates the discomfort associated with nausea
and vomiting. The Reliefband wearable solution has been an industry
leader for more than 20 years and is available OTC, at
Reliefband.com and Amazon.com.
About ReletexTMReletex is an
advanced pulse generator that utilizes neuromodulation technology.
It is the First-Class II neuromodulation device cleared by the FDA
for the therapy of nausea and vomiting. Reletex is a single patient
use device and can function with its included set of
non-replaceable/non-rechargeable batteries for approximately 150
hours when used on setting 3. Reletex is available by prescription
for the treatment of nausea and vomiting as an adjunct to
antiemetics.
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine and wellness company
dedicated to improving health through its non-invasive vagus nerve
stimulation (“nVNS”) technology platform. Our focus is the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking StatementsThis
press release and other written and oral statements made by
representatives of electroCore may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include, but
are not limited to, statements about electroCore's business
prospects and clinical and product development plans; its pipeline
or potential markets for its technologies; the timing, outcome and
impact of regulatory, clinical and commercial developments; the
Company’s business prospects through distribution of Reletex within
the Department of Veterans Affairs or other FSS eligible entities
or other new markets or other distribution agreements and other
statements that are not historical in nature, particularly those
that utilize terminology such as "anticipates," "will," "expects,"
"believes," "intends," other words of similar meaning, derivations
of such words and the use of future dates. Actual results could
differ from those projected in any forward-looking statements due
to numerous factors. Such factors include, among others, the
ability to raise the additional funding needed to continue to
pursue electroCore’s business and product development plans, the
inherent uncertainties associated with developing new products or
technologies, the ability to commercialize gammaCore™, the
potential impact and effects of COVID-19 on the business of
electroCore, electroCore’s results of operations and financial
performance, and any measures electroCore has and may take in
response to COVID-19 and any expectations electroCore may have with
respect thereto, competition in the industry in which electroCore
operates and overall market conditions. Any forward-looking
statements are made as of the date of this press release, and
electroCore assumes no obligation to update the forward-looking
statements or to update the reasons why actual results could differ
from those projected in the forward-looking statements, except as
required by law. Investors should consult all of the information
set forth herein and should also refer to the risk factor
disclosure set forth in the reports and other documents electroCore
files with the SEC available at www.sec.gov.
Contact:ECOR Investor Relations(973)
302-9253investors@electrocore.com
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2024 to Jul 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2023 to Jul 2024